Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption

Alejandro Orlowski, Thomas Weber

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    2 Scopus citations

    Abstract

    One of the greatest barriers for the use of adeno-associated vectors (AAV) in gene therapy is the presence of pre-existing antibodies against AAV in the general population. Since many of the anti-AAV antibodies have the ability to neutralize the transduction target tissues, even patients with low antibody titers must be excluded from clinical trials or therapy. In recent years, various methods have been proposed to overcome this problem, unfortunately with limited success. In this chapter, we describe in detail a protocol for hemapheresis with an immunoadsorption matrix to remove specifically anti-AAV antibodies in an in vivo rat model. Furthermore, this chapter describes in detail the methods to determine the efficiency of hemapheresis and immunoadsorption.

    Original languageEnglish
    Title of host publicationMethods in Molecular Biology
    PublisherHumana Press Inc.
    Pages235-248
    Number of pages14
    DOIs
    StatePublished - 2022

    Publication series

    NameMethods in Molecular Biology
    Volume2573
    ISSN (Print)1064-3745
    ISSN (Electronic)1940-6029

    Keywords

    • Adeno-associated virus
    • Hemapheresis
    • Immunoadsorption
    • Neutralization assay
    • Neutralizing antibodies
    • Plasmapheresis

    Fingerprint

    Dive into the research topics of 'Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption'. Together they form a unique fingerprint.

    Cite this